SR One, AbbVie Ventures, Takeda Ventures and Pfizer Ventures all returned having already backed the cancer and inflammatory disease drug developer at series A stage.

The healthcare-focused workplace management software provider hiked its total funding to about $225m as Ascension Ventures reinvested.

Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer with backing from returning investor MRL Ventures Fund.

GV participated in a round that increased the on-demand healthcare service's overall funding to $107m, with the cash to go to expanding its operations.

SR One, AbbVie Ventures, Takeda Ventures and Pfizer Ventures all returned for the cancer and inflammatory disease drug developer's series B.

Blue Venture Fund took part in a $61.8m round for the testing services provider, and managing director Anna Haghgooie will join PWNHealth’s board.

Carrie Hurwitz Williams has been promoted from principal while Jennifer Carter will add the role to her vice-president of portfolio development, marketing and venture operations position.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

University hospital Charité’s sinus surgery spinout Fiagon Medical has been acquired for more than $70m, with Cascara Ventures and Donghai Securities also scoring exits.

Graphite Bio's first drug program will target sickle cell anaemia based on innovations in DNA editing from Stanford University.